149 related articles for article (PubMed ID: 25393798)
21. First-line crizotinib versus chemotherapy in ALK-positive lung cancer.
Solomon BJ; Mok T; Kim DW; Wu YL; Nakagawa K; Mekhail T; Felip E; Cappuzzo F; Paolini J; Usari T; Iyer S; Reisman A; Wilner KD; Tursi J; Blackhall F;
N Engl J Med; 2014 Dec; 371(23):2167-77. PubMed ID: 25470694
[TBL] [Abstract][Full Text] [Related]
22. ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma.
Bresler SC; Weiser DA; Huwe PJ; Park JH; Krytska K; Ryles H; Laudenslager M; Rappaport EF; Wood AC; McGrady PW; Hogarty MD; London WB; Radhakrishnan R; Lemmon MA; Mossé YP
Cancer Cell; 2014 Nov; 26(5):682-94. PubMed ID: 25517749
[TBL] [Abstract][Full Text] [Related]
23. Discovery of Inhibitors That Overcome the G1202R Anaplastic Lymphoma Kinase Resistance Mutation.
Hatcher JM; Bahcall M; Choi HG; Gao Y; Sim T; George R; Jänne PA; Gray NS
J Med Chem; 2015 Dec; 58(23):9296-9308. PubMed ID: 26568289
[TBL] [Abstract][Full Text] [Related]
24. Erratum to: Alectinib: A Review of Its Use in Advanced ALK-Rearranged Non-Small Cell Lung Cancer.
McKeage K
Drugs; 2015 Feb; 75(2):241. PubMed ID: 25586273
[No Abstract] [Full Text] [Related]
25. Identification of I1171N resistance mutation in ALK-positive non-small-cell lung cancer tumor sample and circulating tumor DNA.
Johnson AC; Dô P; Richard N; Dubos C; Michels JJ; Bonneau J; Gervais R
Lung Cancer; 2016 Sep; 99():38-40. PubMed ID: 27565911
[TBL] [Abstract][Full Text] [Related]
26. ALK inhibitors in non-small cell lung cancer: the latest evidence and developments.
Sullivan I; Planchard D
Ther Adv Med Oncol; 2016 Jan; 8(1):32-47. PubMed ID: 26753004
[TBL] [Abstract][Full Text] [Related]
27. Dose-Dependent Mutation Rates Determine Optimum Erlotinib Dosing Strategies for EGFR Mutant Non-Small Cell Lung Cancer Patients.
Liu LL; Li F; Pao W; Michor F
PLoS One; 2015; 10(11):e0141665. PubMed ID: 26536620
[TBL] [Abstract][Full Text] [Related]
28. Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.
Peters S; Camidge DR; Shaw AT; Gadgeel S; Ahn JS; Kim DW; Ou SI; Pérol M; Dziadziuszko R; Rosell R; Zeaiter A; Mitry E; Golding S; Balas B; Noe J; Morcos PN; Mok T;
N Engl J Med; 2017 Aug; 377(9):829-838. PubMed ID: 28586279
[TBL] [Abstract][Full Text] [Related]
29. TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.
Amin AD; Li L; Rajan SS; Gokhale V; Groysman MJ; Pongtornpipat P; Tapia EO; Wang M; Schatz JH
Oncotarget; 2016 Apr; 7(17):23715-29. PubMed ID: 27009859
[TBL] [Abstract][Full Text] [Related]
30. NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.
Mologni L; Ceccon M; Pirola A; Chiriano G; Piazza R; Scapozza L; Gambacorti-Passerini C
Oncotarget; 2015 Mar; 6(8):5720-34. PubMed ID: 25749034
[TBL] [Abstract][Full Text] [Related]
31. Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK.
Fontana D; Ceccon M; Gambacorti-Passerini C; Mologni L
Cancer Med; 2015 Jul; 4(7):953-65. PubMed ID: 25727400
[TBL] [Abstract][Full Text] [Related]
32. Anaplastic lymphoma kinase inhibition in metastatic non-small cell lung cancer: clinical impact of alectinib.
Muller IB; de Langen AJ; Giovannetti E; Peters GJ
Onco Targets Ther; 2017; 10():4535-4541. PubMed ID: 28979145
[TBL] [Abstract][Full Text] [Related]
33. Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer: Results From PROFILE 1014.
Solomon BJ; Cappuzzo F; Felip E; Blackhall FH; Costa DB; Kim DW; Nakagawa K; Wu YL; Mekhail T; Paolini J; Tursi J; Usari T; Wilner KD; Selaru P; Mok TS
J Clin Oncol; 2016 Aug; 34(24):2858-65. PubMed ID: 27022118
[TBL] [Abstract][Full Text] [Related]
34. A novel acquired ALK F1245C mutation confers resistance to crizotinib in ALK-positive NSCLC but is sensitive to ceritinib.
Kodityal S; Elvin JA; Squillace R; Agarwal N; Miller VA; Ali SM; Klempner SJ; Ou SH
Lung Cancer; 2016 Feb; 92():19-21. PubMed ID: 26775591
[TBL] [Abstract][Full Text] [Related]
35. Alectinib: a novel second generation anaplastic lymphoma kinase (ALK) inhibitor for overcoming clinically-acquired resistance.
Song Z; Wang M; Zhang A
Acta Pharm Sin B; 2015 Jan; 5(1):34-7. PubMed ID: 26579422
[TBL] [Abstract][Full Text] [Related]
36. Intermittent high-dose treatment with erlotinib enhances therapeutic efficacy in EGFR-mutant lung cancer.
Schöttle J; Chatterjee S; Volz C; Siobal M; Florin A; Rokitta D; Hinze Y; Dietlein F; Plenker D; König K; Albus K; Heuckmann JM; Rauh D; Franz T; Neumaier B; Fuhr U; Heukamp LC; Ullrich RT
Oncotarget; 2015 Nov; 6(36):38458-68. PubMed ID: 26540572
[TBL] [Abstract][Full Text] [Related]
37. Clinical Implications of Variant ALK FISH Rearrangement Patterns.
Gao X; Sholl LM; Nishino M; Heng JC; Jänne PA; Oxnard GR
J Thorac Oncol; 2015 Nov; 10(11):1648-52. PubMed ID: 26536196
[TBL] [Abstract][Full Text] [Related]
38. Targeting stemness is an effective strategy to control EML4-ALK+ non-small cell lung cancer cells.
Oh SJ; Noh KH; Lee YH; Hong SO; Song KH; Lee HJ; Kim S; Kim TM; Jeon JH; Seo JH; Kim DW; Kim TW
Oncotarget; 2015 Nov; 6(37):40255-67. PubMed ID: 26517679
[TBL] [Abstract][Full Text] [Related]
39. PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations.
Zou HY; Li Q; Engstrom LD; West M; Appleman V; Wong KA; McTigue M; Deng YL; Liu W; Brooun A; Timofeevski S; McDonnell SR; Jiang P; Falk MD; Lappin PB; Affolter T; Nichols T; Hu W; Lam J; Johnson TW; Smeal T; Charest A; Fantin VR
Proc Natl Acad Sci U S A; 2015 Mar; 112(11):3493-8. PubMed ID: 25733882
[TBL] [Abstract][Full Text] [Related]
40. Anaplastic lymphoma kinase rearrangement in lung cancer: its biological and clinical significance.
Toyokawa G; Seto T
Respir Investig; 2014 Nov; 52(6):330-8. PubMed ID: 25453376
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
